Patents Assigned to Shifa Biomedical Corporation
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10947220
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 16, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10899748
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 10259804
    Abstract: Endothelial Lipase (EL) inhibitors and methods of using such inhibitors for treating conditions implicating EL are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of EL function that can be used therapeutically to raise HDL cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including, but not limited to, familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, and, more generally, cardiovascular disease (CVD).
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: April 16, 2019
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Nabil Elshourbagy, Shaker Mousa, Harold Meyers
  • Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
    Patent number: 10131637
    Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 20, 2018
    Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher Education
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
    Patent number: 9682085
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 20, 2017
    Assignee: Shifa Biomedical Corporation
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil Elshourbagy, Harold Meyers, Shaker A. Mousa